Dr Anthony Fauci, Director of the US National Institute of Allergy and Infectious Diseases and the US President's chief medical adviser, said on Sunday that the data needed to determine the advisability of booster shots of the Moderna Inc (Nasdaq:MRNA) and Johnson & Johnson (NYSE:JNJ) COVID-19 vaccines is just weeks away, Reuters news agency reported on Monday.
On 17 September 2021, a US Food and Drug Administration advisory panel had recommended a third shot of the two-dose Pfizer (NYSE:PFE)/BioNTech (Nasdaq:BNTX) COVID-19 vaccine for people age 65 and older or at high risk of severe COVID-19, but declined to endorse boosters for the wider population.
People who have received the two-dose Moderna vaccine or one-dose J&J vaccine are still awaiting guidance on possible booster shots.
Dr Fauci added that more data may also show a broader need for booster shots across the general US population.
Health officials reportedly indicated that they expected boosters would ultimately be recommended for a broad range of the population, but urged Americans not to seek booster doses until FDA approval is received.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial